Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans.
BACKGROUND:The current strategy for the elimination of onchocerciasis is based on annual or bi-annual mass drug administration with ivermectin. However, due to several limiting factors there is a growing concern that elimination of onchocerciasis cannot be achieved solely through the current strateg...
Main Authors: | Parakkal Jovvian George, Jessica A Hess, Sonia Jain, John B Patton, Tingting Zhan, Nancy Tricoche, Bin Zhan, Maria Elena Bottazzi, Peter J Hotez, David Abraham, Sara Lustigman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-09-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC6762197?pdf=render |
Similar Items
-
Co-Administration of Adjuvanted Recombinant <i>Ov</i>-103 and <i>Ov</i>-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine <i>Onchocerca ochengi</i> Infection Model of Human Onchocerciasis
by: Lisa Luu, et al.
Published: (2022-05-01) -
The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
by: Fidelis Cho-Ngwa, et al.
Published: (2010-08-01) -
Prediction and validation of the structural features of Ov58GPCR, an immunogenic determinant of Onchocerca volvulus.
by: Robert Adamu Shey, et al.
Published: (2018-01-01) -
Patent infections with soil-transmitted helminths and Schistosoma mansoni are not associated with increased prevalence of antibodies to the Onchocerca volvulus peptide epitopes OvMP-1 and OvMP-23
by: Johnny Vlaminck, et al.
Published: (2019-01-01) -
The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates.
by: Jing Wang, et al.
Published: (2012-01-01)